Clinical Trial Update: Vandetanib in Advanced NSCLC With RET Rearrangement [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating vandetanib in advanced non-small cell lung cancer with RET rearrangement has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Vandetanib (vandetanib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED